Vācija -
angļu -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
oxaliplatin winthrop 5 mg/ml konzentrat zur herstellung einer infusionslösung
Vācija -
angļu -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
oxaliplatin ribosepharm 5 mg/ml konzentrat zur herstellung einer infusionslösung
Īrija -
angļu -
HPRA (Health Products Regulatory Authority)
oxaliplatin 5mg/ml concentrate for solution for infusion
accord healthcare ireland ltd. - oxaliplatin - concentrate for solution for infusion - 5 milligram(s)/millilitre - platinum compounds; oxaliplatin
Zviedrija -
angļu -
Läkemedelsverket (Medical Products Agency)
oxaliplatin vianex 5 mg/ml pulver till infusionsvätska, lösning
Kanāda -
angļu -
Health Canada
oxaliplatin for injection powder for solution
hospira healthcare ulc - oxaliplatin - powder for solution - 50mg - oxaliplatin 50mg - antineoplastic agents
Kanāda -
angļu -
Health Canada
oxaliplatin for injection powder for solution
hospira healthcare ulc - oxaliplatin - powder for solution - 100mg - oxaliplatin 100mg - antineoplastic agents
Zviedrija -
angļu -
Läkemedelsverket (Medical Products Agency)
oxaliplatin eugia 5 mg/ml koncentrat till infusionsvätska, lösning
Kanāda -
angļu -
Health Canada
act oxaliplatin powder for solution
actavis pharma company - oxaliplatin - powder for solution - 50mg - oxaliplatin 50mg - antineoplastic agents
Kanāda -
angļu -
Health Canada
act oxaliplatin powder for solution
actavis pharma company - oxaliplatin - powder for solution - 100mg - oxaliplatin 100mg - antineoplastic agents
Austrālija -
angļu -
Department of Health (Therapeutic Goods Administration)
oxaliplatin wkt oxaliplatin 100mg/20 ml concentrate for solution for infusion vial
wockhardt bio pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; nitrogen - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.